Posts

FDA Places Partial Hold on Biohaven’s Epilepsy Drug After $350 Million Licensing Deal

on
Biohaven said the FDA placed a partial clinical hold on trials of opakalim (BHV-7000), its experimental treatment for focal-onset epilepsy, on September 10, 2026. The hold pauses enrollment of new participants while the FDA reviews safety information. Existing participants may continue under the agency’s conditions; available reports did not indicate that the drug’s development had been terminated. The announcement came roughly two weeks after Biohaven agreed to license opakalim and its broader Kv7 platform to SK Biopharmaceuticals. Under the deal, Biohaven is due $350 million at closing and another $50 million one year later. The agreement could be worth up to $795 million, including development and regulatory milestones, plus royalties. Opakalim is being tested in Phase 2/3 studies, with pivotal RISE3 results previously expected in the second half of 2026. The FDA hold creates uncertainty around the trial timeline and the drug’s eventual approval prospects. Sources: Bioha...

FDA expands Bayer’s Hyrnuo into first-line HER2-mutant lung cancer

on

FDA signals flexibility on psychedelic drug review while keeping evidence standards

on

FDA makes acting CBER and CDER leaders permanent

on

Encoded closes $275M Series F to advance Dravet syndrome drug ETX101

on

Tyra shares slide after bladder-cancer drug misses investor efficacy bar

on

Tyra’s bladder-cancer data offer a bright spot—but miss investor expectations

on

Beeline’s oral lupus drug afimetoran delivers positive Phase 2 results

on

Drug-pricing policy upheaval forces pharma companies to rethink global launch strategies

on

Evommune abandons hope for EVO756 as an itch drug after latest Phase 2 failure

on

FDA Makes CDER and CBER Leadership Permanent While Commissioner Nominee Awaits Senate Confirmation

on

Solstice Oncology raises $225M to advance next-generation CTLA-4 therapy

on

Encoded raises $275M to push Dravet gene therapy toward registration

on